| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |

* Unidad de Biofísica (CSIC-UPV/EHU) and Departamento de Bioquímica, Universidad del País Vasco, 48080 Bilbao, Spain; and
Department of Molecular Biophysics and Physiology, Rush Medical College, Chicago, Illinois 60612 USA
Correspondence: Address reprint requests to Dr. José L. Nieva, Tel.: +34-94-6013353; Fax: +34-94-4643360; E-mail: gbpniesj{at}lg.ehu.es.
The membrane-proximal segment connecting the helical core with the transmembrane anchor of human immunodeficiency virus type 1 gp41 is accessible to broadly neutralizing antibodies and plays a crucial role in fusion activity. New predictive approaches including computation of interfacial affinity and the corresponding hydrophobic moments suggest that this region is functionally segmented into two consecutive subdomains: one amphipathic at the N-terminal side and one fully interfacial at the C-terminus. The N-terminal subdomain would extend
-helices from the preceding carboxy-terminal heptad repeat and provide, at the same time, a hydrophobic-at-interface surface. Experiments were performed to compare a wild-type representing pretransmembrane peptide with a nonamphipathic defective sequence, which otherwise conserved interfacial hydrophobicity at the carboxy-subdomain. Results confirmed that both penetrated equally well into lipid monolayers and both were able to partition into membrane interfaces. However only the functional sequence: 1), adopted helical structures in solution and in membranes; 2), formed homo-oligomers in solution and membranes; and 3), inhibited gp41-induced cell-cell fusion. These data support two roles for gp41 aromatic-rich pretransmembrane sequence: 1), oligomerization of gp41; and 2), immersion into the viral membrane interface. Accessibility to membrane interfaces and subsequent adoption of the low-energy structure may augment helical bundle formation and perhaps be related to a concomitant loss of immunoreactivity. These results may have implications in the development of HIV-1 fusion inhibitors and vaccines.
This article has been cited by other articles:
![]() |
N. Huarte, M. Lorizate, R. Maeso, R. Kunert, R. Arranz, J. M. Valpuesta, and J. L. Nieva The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 4E10 Monoclonal Antibody Is Better Adapted to Membrane-Bound Epitope Recognition and Blocking than 2F5 J. Virol., September 15, 2008; 82(18): 8986 - 8996. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Howard, E. A. Travanty, S. A. Jeffers, M. K. Smith, S. T. Wennier, L. B. Thackray, and K. V. Holmes Aromatic Amino Acids in the Juxtamembrane Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Are Important for Receptor-Dependent Virus Entry and Cell-Cell Fusion J. Virol., March 15, 2008; 82(6): 2883 - 2894. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Hager-Braun, H. Katinger, and K. B. Tomer The HIV-Neutralizing Monoclonal Antibody 4E10 Recognizes N-Terminal Sequences on the Native Antigen. J. Immunol., June 15, 2006; 176(12): 7471 - 7481. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Broer, B. Boson, W. Spaan, F.-L. Cosset, and J. Corver Important Role for the Transmembrane Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Protein during Entry J. Virol., February 1, 2006; 80(3): 1302 - 1310. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Guillen, A. J. Perez-Berna, M. R. Moreno, and J. Villalain Identification of the Membrane-Active Regions of the Severe Acute Respiratory Syndrome Coronavirus Spike Membrane Glycoprotein Using a 16/18-Mer Peptide Scan: Implications for the Viral Fusion Mechanism J. Virol., February 1, 2005; 79(3): 1743 - 1752. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Zwick, R. Jensen, S. Church, M. Wang, G. Stiegler, R. Kunert, H. Katinger, and D. R. Burton Anti-Human Immunodeficiency Virus Type 1 (HIV-1) Antibodies 2F5 and 4E10 Require Surprisingly Few Crucial Residues in the Membrane-Proximal External Region of Glycoprotein gp41 To Neutralize HIV-1 J. Virol., January 15, 2005; 79(2): 1252 - 1261. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |